195 related articles for article (PubMed ID: 33588260)
1. Prompt improvement of difficulty with sleep initiation and waking up in the morning and daytime somnolence by combination therapy of suvorexant and ramelteon in delayed sleep-wake phase disorder: a case series of three patients.
Izuhara M; Kawano K; Otsuki K; Hashioka S; Inagaki M
Sleep Med; 2021 Apr; 80():100-104. PubMed ID: 33588260
[TBL] [Abstract][Full Text] [Related]
2. Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients.
Kawada K; Ohta T; Tanaka K; Miyamura M; Tanaka S
J Stroke Cerebrovasc Dis; 2019 Jan; 28(1):142-148. PubMed ID: 30322756
[TBL] [Abstract][Full Text] [Related]
3. Non-24-hour sleep-wake disorder successfully treated with the combination of ramelteon and suvorexant in a case of autism spectrum disorder.
Iwata M; Kaneko K
Neuropsychopharmacol Rep; 2020 Dec; 40(4):383-387. PubMed ID: 32990413
[TBL] [Abstract][Full Text] [Related]
4. Residual effects of low dose of suvorexant, zolpidem, and ramelteon in healthy elderly subjects: A randomized double-blind study.
Uemura SI; Imanishi A; Terui Y; Park I; Satake M; Han G; Shioya T; Kanbayashi T; Nishino S
Neuropsychopharmacol Rep; 2022 Sep; 42(3):288-298. PubMed ID: 35748642
[TBL] [Abstract][Full Text] [Related]
5. Suvorexant: scientifically interesting, utility uncertain.
Keks NA; Hope J; Keogh S
Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
[TBL] [Abstract][Full Text] [Related]
6. Ultra-low-dose early night ramelteon administration for the treatment of delayed sleep-wake phase disorder: case reports with a pharmacological review.
Shimura A; Kanno T; Inoue T
J Clin Sleep Med; 2022 Dec; 18(12):2861-2865. PubMed ID: 35929592
[TBL] [Abstract][Full Text] [Related]
7. The role of suvorexant in the prevention of delirium during acute hospitalization: A systematic review.
Adams AD; Pepin MJ; Brown JN
J Crit Care; 2020 Oct; 59():1-5. PubMed ID: 32480359
[TBL] [Abstract][Full Text] [Related]
8. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience.
Matsumura T; Terada J; Yoshimura C; Koshikawa K; Kinoshita T; Yahaba M; Nagashima K; Sakao S; Tatsumi K
Drug Des Devel Ther; 2019; 13():809-816. PubMed ID: 30880914
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of add-on ramelteon and subsequent dose reduction in benzodiazepine derivatives/Z-drugs for the treatment of sleep-related eating disorder and night eating syndrome: a retrospective analysis of consecutive patients.
Matsui K; Kuriyama K; Kobayashi M; Inada K; Nishimura K; Inoue Y
J Clin Sleep Med; 2021 Jul; 17(7):1475-1483. PubMed ID: 33704048
[TBL] [Abstract][Full Text] [Related]
10. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
Patel KV; Aspesi AV; Evoy KE
Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
[TBL] [Abstract][Full Text] [Related]
11. Suvorexant in the Treatment of Difficulty Falling and Staying Asleep (Insomnia).
Berger AA; Sottosanti ER; Winnick A; Keefe J; Gilbert E; Hasoon J; Thase ME; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2022 Feb; 52(1):68-90. PubMed ID: 35342199
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study.
Ozone M; Hirota S; Ariyoshi Y; Hayashida K; Ikegami A; Habukawa M; Ohshima H; Harada D; Hiejima H; Kotorii N; Murotani K; Taninaga T; Uchimura N
Adv Ther; 2024 Apr; 41(4):1728-1745. PubMed ID: 38460107
[TBL] [Abstract][Full Text] [Related]
13. Ramelteon for the treatment of insomnia.
Borja NL; Daniel KL
Clin Ther; 2006 Oct; 28(10):1540-55. PubMed ID: 17157111
[TBL] [Abstract][Full Text] [Related]
14. Induced next-day somnolence in an elderly patient taking suvorexant concomitantly with diltiazem.
Shihyakugari A; Hori S; Miki A; Sawada Y
Int J Clin Pharmacol Ther; 2016 Aug; 54(8):645-8. PubMed ID: 27191770
[TBL] [Abstract][Full Text] [Related]
15. Review of Safety and Efficacy of Sleep Medicines in Older Adults.
Schroeck JL; Ford J; Conway EL; Kurtzhalts KE; Gee ME; Vollmer KA; Mergenhagen KA
Clin Ther; 2016 Nov; 38(11):2340-2372. PubMed ID: 27751669
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapies for sleep disturbances in Alzheimer's disease.
McCleery J; Cohen DA; Sharpley AL
Cochrane Database Syst Rev; 2014 Mar; (3):CD009178. PubMed ID: 24659320
[TBL] [Abstract][Full Text] [Related]
17. Effect of Suvorexant vs Placebo on Total Daytime Sleep Hours in Shift Workers: A Randomized Clinical Trial.
Zeitzer JM; Joyce DS; McBean A; Quevedo YL; Hernandez B; Holty JE
JAMA Netw Open; 2020 Jun; 3(6):e206614. PubMed ID: 32484552
[TBL] [Abstract][Full Text] [Related]
18. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
[TBL] [Abstract][Full Text] [Related]
19. Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study.
Ishibashi Y; Nishitani R; Shimura A; Takeuchi A; Touko M; Kato T; Chiba S; Ashidate K; Ishiwata N; Ichijo T; Sasabe M
PLoS One; 2020; 15(9):e0238723. PubMed ID: 32916693
[TBL] [Abstract][Full Text] [Related]
20. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
